{
    "nct_id": "NCT06245889",
    "official_title": "A Pilot Study of Neoadjuvant Response-Adapted Chemotherapy With Pembrolizumab in Patients With Stage 2 and 3 Triple Negative Breast Cancer to Determine Early PET and Biomarker Dynamics",
    "inclusion_criteria": "1. Stage II-III TNBC - estrogen receptor (ER) and progesterone receptor (PR) up to and including 10% is eligible\n2. Age â‰¥ 18 years\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n4. Eligible for standard chemo-immunotherapy as determined by treating physician, including consideration of:\n\n   1. Adequate marrow and organ function\n   2. Co-morbid conditions do not preclude the use of chemo-immunotherapy (such as uncontrolled autoimmune disease, or the use of immunosuppressive medications)\n5. Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Patients unable to undergo PET or MRI\n2. Evidence of metastatic disease or loco-regional recurrence (i.e. distant or chest wall recurrence)\n3. Inflammatory breast cancer\n4. Previous treatment with paclitaxel, carboplatin, or immune checkpoint inhibitors",
    "miscellaneous_criteria": ""
}